Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Carter:2017:10.18632/oncotarget.23675,
author = {Carter, P and Alifrangis, C and Cereser, B and Chandrasinghe, P and Del, Bel Belluz L and Fotopoulou, C and Frilling, A and Herzog, T and Moderau, N and Tabassum, N and Krell, J and Stebbing, J},
doi = {10.18632/oncotarget.23675},
journal = {Oncotarget},
pages = {6007--6014},
title = {Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy},
url = {http://dx.doi.org/10.18632/oncotarget.23675},
volume = {9},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Tumor molecular profiling has enabled selection of targeted therapies in a host of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit of tailoring treatments for female genital tract malignancy, using tumor molecular profiles. Clinical outcome data for 112 patients was retrospectively separated into two groups. These either followed a matched treatment plan that incorporated at least one drug recommended according to their tumor profile and none that were expected to have no benefit (64 patients), or was unmatched with suggested treatments and received at least one drug that was anticipated to lack benefit for that tumor (48 patients).In the group of patients whose drugs matched those recommended by molecular profiling of their tumor, their overall survival was 593 days on average, compared to 449 days for patients that did not; removing drugs predicted to have no benefit from treatment regimens received after profiling increased survival by 144 days on average (P = 0.0265). In the matched treatment group, 30% of patients had died by the last time of monitoring, whereas this was 40% in the unmatched group (P = 0.2778). The IHC biomarker for the progesterone receptor was demonstrated to be prognostic for survival.
AU  - Carter,P
AU  - Alifrangis,C
AU  - Cereser,B
AU  - Chandrasinghe,P
AU  - Del,Bel Belluz L
AU  - Fotopoulou,C
AU  - Frilling,A
AU  - Herzog,T
AU  - Moderau,N
AU  - Tabassum,N
AU  - Krell,J
AU  - Stebbing,J
DO  - 10.18632/oncotarget.23675
EP  - 6014
PY  - 2017///
SN  - 1949-2553
SP  - 6007
TI  - Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.23675
UR  - http://hdl.handle.net/10044/1/56270
VL  - 9
ER  -
Download